JP2023528292A5 - - Google Patents

Info

Publication number
JP2023528292A5
JP2023528292A5 JP2022571242A JP2022571242A JP2023528292A5 JP 2023528292 A5 JP2023528292 A5 JP 2023528292A5 JP 2022571242 A JP2022571242 A JP 2022571242A JP 2022571242 A JP2022571242 A JP 2022571242A JP 2023528292 A5 JP2023528292 A5 JP 2023528292A5
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
chloro
trifluoromethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528292A (ja
Filing date
Publication date
Priority claimed from EP20175820.8A external-priority patent/EP3912625A1/en
Application filed filed Critical
Publication of JP2023528292A publication Critical patent/JP2023528292A/ja
Publication of JP2023528292A5 publication Critical patent/JP2023528292A5/ja
Pending legal-status Critical Current

Links

JP2022571242A 2020-05-20 2021-05-20 脆弱X関連障害の処置のためのmaxi-Kカリウムチャネルオープナー Pending JP2023528292A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20175820.8A EP3912625A1 (en) 2020-05-20 2020-05-20 Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
EP20175820.8 2020-05-20
PCT/EP2021/063463 WO2021234084A1 (en) 2020-05-20 2021-05-20 Maxi-k potassium channel openers for the treatment of fragile x associated disorders

Publications (2)

Publication Number Publication Date
JP2023528292A JP2023528292A (ja) 2023-07-04
JP2023528292A5 true JP2023528292A5 (https=) 2024-05-28

Family

ID=70802691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571242A Pending JP2023528292A (ja) 2020-05-20 2021-05-20 脆弱X関連障害の処置のためのmaxi-Kカリウムチャネルオープナー

Country Status (16)

Country Link
US (1) US20240351994A1 (https=)
EP (2) EP3912625A1 (https=)
JP (1) JP2023528292A (https=)
KR (1) KR20230016194A (https=)
CN (1) CN115666554A (https=)
AU (1) AU2021274879A1 (https=)
BR (1) BR112022023318A2 (https=)
CA (1) CA3177423A1 (https=)
DK (1) DK4153170T3 (https=)
FI (1) FI4153170T3 (https=)
IL (1) IL297493A (https=)
MX (1) MX2022014461A (https=)
PH (1) PH12022553155A1 (https=)
PL (1) PL4153170T3 (https=)
PT (1) PT4153170T (https=)
WO (1) WO2021234084A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250170120A1 (en) * 2022-01-31 2025-05-29 The Board Of Regents Of The University Of Texas System Allosteric sting modulators and methods of use
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
JP2000191661A (ja) * 1998-12-25 2000-07-11 Mitsubishi-Tokyo Pharmaceuticals Inc 環状アミド化合物
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
MXPA03000032A (es) 2000-06-29 2003-08-19 Neurosearch As Uso de derivados de oxindol 3-sustituidos como moduladores de los canales de potasio kcnq.
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
EP1363624A2 (en) 2001-02-20 2003-11-26 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
GEP20074230B (en) 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
JP4989976B2 (ja) * 2004-02-13 2012-08-01 プレジデント アンド フェロウズ オブ ハーバード カレッジ 翻訳開始阻害剤としての3−3−二置換オキシインドール
US20070299102A1 (en) * 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
JP2010525024A (ja) * 2007-04-24 2010-07-22 トポターゲット・アクティーゼルスカブ 置換3−(4−ヒドロキシフェニル)−インドリン−2−オン化合物
FR2920023B1 (fr) * 2007-08-16 2013-02-08 Sanofi Aventis Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
US8703775B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
JO3032B1 (ar) * 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
EP2540295A1 (en) 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
JP6370368B2 (ja) 2013-03-27 2018-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Brd4阻害剤としてのインドリノン類似体
US20180318285A1 (en) * 2015-03-10 2018-11-08 President And Fellows Of Harvard College Methods for treatment of autism spectrum disorders
EP3601235B1 (en) * 2017-03-30 2026-03-04 XWPharma Ltd. Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
WO2020183307A1 (en) * 2019-03-08 2020-09-17 The University Of Buea Dihydro-spiro[indoline-3:1'-isoquinolin]-2-ones and their analogues and derivatives and methods of treating cancer and other diseases

Similar Documents

Publication Publication Date Title
RU2720237C2 (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
US10231967B2 (en) Compounds and their use as BACE inhibitors
TWI535442B (zh) A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
CN113214287B (zh) Hpk1抑制剂及其使用方法
TW202200552A (zh) 作為用於免疫活化之DGKζ抑制劑之經取代胺基噻唑
CN105189506A (zh) 用于治疗寄生虫疾病的化合物和组合物
EA032621B1 (ru) Индазолкарбоксамиды, способы их получения, содержащие их фармацевтические препараты и их применение для изготовления лекарственных средств
US20160045505A1 (en) Compounds and compositions for the treatment of parasitic diseases
EA023420B1 (ru) Замещенные имидазопиридазины
JP7269928B2 (ja) インドールアミン 2,3-ジオキシゲナーゼ(ido)阻害剤としての新規の置換ビアリール化合物
JP2025517733A (ja) ヘテロアレーン、それを含む医薬組成物、及びその使用方法
WO2014151630A2 (en) Compounds and compositions for the treatment of parasitic diseases
JP2016514711A (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
JP2023528292A5 (https=)
EA030823B1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТОЗОЙНОЙ ПРОТЕОСОМЫ ДЛЯ ЛЕЧЕНИЯ ПАРАЗИТАРНОГО ЗАБОЛЕВАНИЯ, ТАКОГО КАК ЛЕЙШМАНИОЗ
AU2023357827A1 (en) Cyclopentane compound
US20240076291A1 (en) Modified isoindolinones as glucosylceramide synthase inhibitors
KR20260041885A (ko) 표적화된 단백질 분해를 위한 치환된 피페리딘디온
US20260124201A1 (en) Cyclopentane compound
JP2025158955A (ja) シクロペンタン化合物を含む医薬組成物
US20240287022A1 (en) Il4i1 inhibitors and methods of use
EA053099B1 (ru) Циклопентановое соединение
HK40057478B (zh) Hpk1抑制剂及其使用方法
EA047452B1 (ru) Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead